Clinical Trial Search

Primary: Average Pain Intensity Numerical Rating Scale (PI-NRS) Score - From 0 to 4 Hours Post-dose — 2.08; 2.73; 1.95; 2.04 Units on a scale

Primary: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 — 0.24; 2.4 cooling uses/day

Primary: Carbamazepine Affects Pain in Patients With S241T NaV1.7 IEM Mutation — 3015; 136; 6360; 915 minutes

Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares

Primary: Change From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight…

Primary: The Hospital Anxiety and Depression Scale (HADS) — 4.6; 1.9 score on a scale

Primary: Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week…

Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants

Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants

Primary: Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4 — 3.04; 2.90; 2.98; 3.14 units on a scale — p=0.6513

Primary: Gastric Emptying Time — 105; 180 minutes — p=0.036

Primary: Duration of Direct Sunlight Exposure Between 10:00 and 18:00 Hours on Days When no Pain Was Experienced (Pain Score of 0). — 69.4; 40.8 hours

Primary: Time in Direct Sunlight Between 10:00-15:00 on Pain-free Days — 8.25; 0.75 Hours

Primary: Change in Erythrocyte Protoporphyrin Levels — 2314.6; 2240.4 µg/dL

Primary: Number of Participants With Partial Response to Dabrafenib and Trametinib — 4 Participants

Primary: Cumulative Number of Days of Phototoxic Reactions (Study Efficacy Population) — 39; 45; 129; 179 Days

Primary: Carotid Artery Stiffness (Expressed by Beta-stiffness Index ) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From…

Primary: Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline — 2.60; 1.98 meter/meter

Primary: Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain…

Primary: Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT) — -2.22; -1.73; -1.30; -1.85 Scores on a Scale

Primary: Change From Baseline Epistaxis Severity Score — -1; -1.1; -1.3; -1.2 units on a scale

Primary: Frequency of Vasospastic Attacks — 2.4; 2.0 attacks per day

Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…

Primary: Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, Baseline — 23.9; 20.4 Units on a scale

Primary: Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale…

Primary: Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS) — 24; 9 participants

Primary: Change in Quality of Life Measured Using the EPP-quality of Life Questionnaire (EPP-QoL). — 27.8; 59.7; 56.9 EPP-QoL score

Primary: Change in Pain Numerical Rating Scale (NRS) — 43.75 units on a scale

Primary: Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean Pain — -1.9447; -1.9786; -1.6798; -1.6633 Points